

Supporting Information

Structural Elucidation and Total Synthesis of Three 9-Norlignans from *Curculigo capitulata*

Song Li,^{†, §} Jin-Hai Yu,^{‡, §} Yao-Yue Fan,^{‡, §} Qun-Fang Liu,[‡] Zhan-Chao Li,[†] Zhi-Xiang Xie,[†]
Ying Li^{*,†} and Jian-Min Yue^{*,‡}

[†]State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, People's Republic of China

[‡]State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai, 201203, People's Republic of China

[§]Authors contributed this work equally.

Table of Contents

Table S1. ^1H (500 MHz) and ^{13}C (125 MHz) NMR spectroscopic data for 1–3	S3
Table S2. Specific optical rotation of natural products and corresponding synthetic compounds	S4
Figure S1. CD curves for compounds 1 , 1a , and 1b	S5
Figure S2. CD curves for compounds 2 , 2a , and 2b	S5
Figure S3. CD curves for compounds 3 , 3a , and 3b	S5
Figure S4. ^1H NMR spectrum of Capitulactone A (1) in CDCl_3	S6
Figure S5. ^{13}C NMR spectrum of Capitulactone A (1) in CDCl_3	S7
Figure S6. ^1H - ^1H COSY spectrum of Capitulactone A (1) in CDCl_3	S8
Figure S7. HSQC spectrum of Capitulactone A (1) in CDCl_3	S9
Figure S8. HMBC spectrum of Capitulactone A (1) in CDCl_3	S10
Figure S9. (+)-ESIMS spectrum of Capitulactone A (1)	S11
Figure S10. (–)-ESIMS spectrum of Capitulactone A (1)	S12
Figure S11. (–)-HRESIMS spectrum of Capitulactone A (1)	S13
Figure S12. ^1H NMR spectrum of Capitulactone B (2) in CDCl_3	S14
Figure S13. ^{13}C NMR spectrum of Capitulactone B (2) in CDCl_3	S15
Figure S14. HSQC spectrum of Capitulactone B (2) in CDCl_3	S16
Figure S15. HMBC spectrum of Capitulactone B (2) in CDCl_3	S17
Figure S16. (+)-ESIMS spectrum of Capitulactone B (2)	S18
Figure S17. (+)-HRESIMS spectrum of Capitulactone B (2)	S19
Figure S18. ^1H NMR spectrum of Capitulactone C (3) in CDCl_3	S20
Figure S19. ^{13}C NMR spectrum of Capitulactone C (3) in CDCl_3	S21
Figure S20. HMBC spectrum of Capitulactone C (3) in CDCl_3	S22
Figure S21. (+)-ESIMS spectrum of Capitulactone C (3)	S23
Figure S22. (–)-ESIMS spectrum of Capitulactone C (3)	S24
Figure S23. (+)-HRESIMS spectrum of Capitulactone C (3)	S25
Total syntheses of 1a, 1b, 3a and 3b	S26
^1H and ^{13}C NMR spectra of synthetic compounds	S40

Table S1. ¹H (500 MHz) and ¹³C (125 MHz) NMR spectroscopic data for 1–3

position	1^a		2^a		3^a	
	δ_{H} (multi, <i>J</i> in Hz)	δ_{C}	δ_{H} (multi, <i>J</i> in Hz)	δ_{C}	δ_{H} (multi, <i>J</i> in Hz)	δ_{C}
1		140.6		140.6		140.6
2		166.4		166.3		166.3
3	5.69, s	95.7	5.69, s	95.7	5.69, s	95.7
4		169.4		169.2		169.2
5	4.52–4.60, m (2H)	62.6	4.52–4.60, m (2H)	62.6	4.54–4.62, m (2H)	62.6
6	6.35, m	127.4	6.34, m	127.4	6.35, m	127.4
7	2.95, dd (15.4, 7.1)	35.6	2.95, dd (15.4, 7.1)	35.6	2.95, dd (15.5, 7.1)	35.6
	2.61, dd (15.4, 6.9)		2.61, dd (15.4, 6.9)		2.61, dd (15.5, 7.0)	
8	4.62, p (6.7)	82.7	4.62, p (6.7)	82.7	4.62, p (6.8)	82.6
9	2.76, m	33.8	2.76, m	33.8	2.76, dddd (15.3, 7.2, 6.6, 1.8)	33.9
	2.65, m		2.65, m		2.67, dddd (15.3, 7.4, 6.3, 1.8)	
1'		129.4		129.3		130.3
2'	7.13, d (8.5)	130.1	7.19, (8.6)	129.9	6.84, d (2.0)	114.7
3'	6.82, d (8.5)	115.3	6.88, (8.6)	113.8		145.3
4'		154.8		158.7		145.7
5'	6.82, d (8.5)	115.3	6.88, (8.6)	113.8	6.83, d (8.3)	110.5
6'	7.13, d (8.5)	130.1	7.19, (8.6)	129.9	6.74, dd (8.3, 2.0)	120.9
7'	6.55, dt (11.6, 1.8)	132.1	6.56, dt (11.6, 1.8)	132.1	6.55, ddd (11.6, 1.8, 1.8)	132.2
8'	5.54, dt (11.6, 7.2)	123.4	5.55, dt (11.6, 7.2)	123.4	5.55, ddd (11.6, 7.4, 7.2)	123.9
OCH3			3.82, s	55.3	3.90, s	56.0
3'-OH					5.61, s	
4'-OH	5.31, s					

^a Data were measured in CDCl₃.

Table S2. Specific optical rotation of natural products and corresponding synthetic compounds.

No	C (g/100ml)	$[\alpha]$	T (°C)	Solvent
1	0.135	-10.7	20	Methanol
1a	0.230	-10.6	20	Methanol
1b	0.285	+11.1	20	Methanol
2	0.138	-13.6	18	Methanol
2a	0.117	-11.9	18	Methanol
2b	0.098	+13.3	18	Methanol
3	0.15	-8.5	20	Methanol
3a	0.450	-13.0	20	Methanol
3b	0.247	+13.8	20	Methanol




Figure S1. CD curves for compounds **1**, **1a**, and **1b**.




Figure S2. CD curves for compounds **2**, **2a**, and **2b**.




Figure S3. CD curves for compounds **3**, **3a**, and **3b**.

Figure S4. ^1H NMR spectrum of Capitulactone A (**1**) in CDCl_3




Figure S5. ^{13}C NMR spectrum of Capitulactone A (**1**) in CDCl_3




Figure S6. ^1H - ^1H COSY spectrum of Capitulactone A (**1**) in CDCl_3




Figure S7. HSQC spectrum of Capitulactone A (**1**) in CDCl₃




Figure S8. HMBC spectrum of Capitulactone A (**1**) in CDCl_3




Figure S9. (+)-ESIMS spectrum of Capitulactone A (1)




Figure S10. (-)-ESIMS spectrum of Capitulactone A (**1**).




Figure S11. (-)-HRESIMS spectrum of Capitulactone A (1)




Figure S12. ^1H NMR spectrum of Capitulacone B (**2**) in CDCl_3




Figure S13. ^{13}C NMR spectrum of Capitulactone B (**2**) in CDCl_3




Figure S14. HSQC spectrum of Capitulactone B (**2**) in CDCl₃




Figure S15. HMBC spectrum of Capitulactone B (**2**) in CDCl₃




Figure S16. (+)-ESIMS spectrum of Capitulactone B (2)




Figure S17. (+)-HRESIMS spectrum of Capitulactone B (2)




Figure S18. ^1H NMR spectrum of Capitulactone C (**3**) in CDCl_3




Figure S19. ^{13}C NMR spectrum of Capitulactone C (**3**) in CDCl_3




Figure S20. HMBC spectrum of Capitulactone C (**3**) in CDCl₃




Figure S21. (+)-ESIMS spectrum of Capitulactone C (**3**)




Figure S22. (-)-ESIMS spectrum of Capitulactone C (3)





Figure S23. (+)-HRESIMS spectrum of Capitulactone C (3)



Total syntheses of 1a, 1b, 3a and 3b

(S)-1-(2-Bromo-4,5-bis((tert-butyldimethylsilyl)oxy)phenyl)-5-(4-(methoxymethoxy)phenyl)pent-4-yn-2-ol ((S)-15a). To a solution of **14** (3.1 g, 19.1 mmol) in dry THF (80 mL) under argon atmosphere was added *n*-BuLi (2.4 M, 9.6 mL, 23.0 mmol) at -78 °C. The mixture was stirred at -78 °C for 1 h, (*R*)-**7a** (9.1 g, 19.1 mmol) in anhydrous THF and BF₃·OEt₂ (2.4 mL, 19.1 mmol) was slowly added. After the completion of the reaction, the resulting solution was quenched with water (20 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic solution was washed with saturated aqueous NaCl (10 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (hexanes/EtOAc, 8:1) to give (*S*)-**15a** (11.2 g, 92%) as a colorless oil. $[\alpha]_{\text{D}}^{20}$ -38.0 (c 1.00, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.36 (d, *J* = 8.7 Hz, 2H), 7.01 (s, 1H), 6.96 (d, *J* = 8.7 Hz, 2H), 6.82 (s, 1H), 5.17 (s, 2H), 4.11 (m, 1H), 3.47 (s, 3H), 3.01 (dd, *J* = 13.7, 5.8 Hz, 1H), 2.87 (dd, *J* = 13.7, 7.3 Hz, 1H), 2.62 (m, 2H), 2.05 (d, *J* = 4.9 Hz, 1H), 0.99 (s, 9H), 0.97 (s, 9H), 0.20 (s, 6H), 0.19 (s, 6H). ¹³C {¹H}NMR (101 MHz, CDCl₃) δ 156.9, 146.4, 146.3, 133.0, 130.0, 124.9, 123.7, 116.7, 116.1, 114.8, 94.3, 84.5, 83.2, 69.7, 56.0, 42.0, 27.4, 25.9, 25.8, 18.43, 18.40, -4.11, -4.14, -4.18, -4.21. IR (KBr) ν_{max} 3451, 3043, 2955, 2930, 2897, 2858, 1606, 1508, 1442, 1385, 1256, 839, 783 cm⁻¹; HRMS (ESI): calcd for C₃₁H₄₈BrO₅Si₂ [M + H]⁺ 635.2218, found 635.2218.

(R)-1-(2-Bromo-4,5-bis((tert-butyldimethylsilyl)oxy)phenyl)-5-(4-(methoxymethoxy)phenyl)pent-4-yn-2-ol ((R)-15b). Prepared according to the above step. Colorless oil (11.0 g, 90%). $[\alpha]_{\text{D}}^{20}$ +34.0 (c 1.00, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.36 (d, *J* = 8.8 Hz, 2H), 7.01 (s, 1H), 6.96 (d, *J* = 8.8 Hz, 2H), 6.83 (s, 1H), 5.17 (s, 2H), 4.16 – 4.05 (m, 1H), 3.47 (s, 3H), 3.01 (dd, *J* = 13.7, 5.8 Hz, 1H), 2.88 (dd, *J* = 13.7, 7.3 Hz, 1H), 2.62 (m, 2H), 1.97 (br, 1H), 0.99 (s, 9H), 0.97 (s, 9H),

0.20 (s, 6H) , 0.19 (s, 6H). ^{13}C $\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 156.9, 146.4, 146.3, 133.0, 130.1, 124.9, 123.7, 116.7, 116.1, 114.8, 94.3, 84.5, 83.2, 69.7, 56.0, 42.0, 27.4, 25.9, 25.8, 18.42, 18.39, -4.11, -4.14, -4.18, -4.21. IR (KBr) ν_{max} 3430, 3054, 2957, 2931, 2899, 2859, 1606, 1508, 1422, 1385, 1265, 1201, 840, 742cm^{-1} ; HRMS (ESI): calcd for $\text{C}_{31}\text{H}_{48}\text{BrO}_5\text{Si}_2$ $[\text{M} + \text{H}]^+$ 635.2218, found 635.2220.

(*S*)-((2-(3-(4-(Methoxymethoxy)phenyl)prop-2-yn-1-yl)-2,3-dihydrobenzofuran-5,6-diyl)bis(oxy))bis(tert-butyldimethylsilane) ((*S*)-16a). To a solution of (*S*)-15a (4.5 g, 7.1 mmol) in dry toluene (100 mL) under argon atmosphere, NaH (60%) (348 mg, 8.7 mmol) was added. The mixture was stirred at 40 °C for 15 min. Then, the mixture was cooled to room temperature and CuCl (28 mg, 0.28 mmol) was added to the solution. The suspension was stirred for 6 h at reflux and after this time, the mixture was filtered through Celite®. Then, the mixture was purified by flash column chromatography (hexanes/EtOAc, 16:1) to give (*S*)-16a (3.7 g, 95%) as a colorless oil. $[\alpha]_{\text{D}}^{20} +37.0$ (c 1.00, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.30 (d, J = 8.8 Hz, 2H), 6.95 (d, J = 8.8 Hz, 2H), 6.66 (s, 1H), 6.36 (s, 1H), 5.16 (s, 2H), 4.94 (m, 1H), 3.46 (s, 3H), 3.30 (dd, J = 15.4, 8.9 Hz, 1H), 3.07 (dd, J = 15.4, 6.6 Hz, 1H), 2.82 (m, 2H), 1.00 (s, 9H), 0.99 (s, 9H), 0.21 (s, 6H), 0.18 (s, 3H), 0.17 (s, 3H). ^{13}C $\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 156.8, 153.4, 146.2, 140.4, 132.9, 117.8, 116.9, 116.7, 115.9, 102.6, 94.1, 83.9, 82.0, 81.2, 55.9, 34.9, 26.5, 25.95, 25.92, 18.4, 18.3, -4.09, -4.12, -4.19, -4.21. IR (KBr) ν_{max} 3053, 2957, 2931, 2899, 2858, 1607, 1508, 1424, 1362, 1265, 1165, 839, 741cm^{-1} ; HRMS (ESI): calcd for $\text{C}_{31}\text{H}_{46}\text{NaO}_5\text{Si}_2$ $[\text{M} + \text{Na}]^+$ 577.2776, found 577.2778.

(*R*)-((2-(3-(4-(Methoxymethoxy)phenyl)prop-2-yn-1-yl)-2,3-dihydrobenzofuran-5,6-diyl)bis(oxy))bis(tert-butyldimethylsilane) ((*R*)-16b). Prepared according to the above step. Colorless oil,

(3.6 g, 93%). $[\alpha]_D^{20}$ -34.0 (c 1.00, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.29 (d, J = 8.7 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 6.64 (s, 1H), 6.34 (s, 1H), 5.16 (s, 2H), 4.93 (m, 1H), 3.47 (s, 3H), 3.29 (dd, J = 15.3, 9.0 Hz, 1H), 3.05 (dd, J = 15.3, 6.6 Hz, 1H), 2.81 (m, 2H), 0.98 (s, 9H), 0.97 (s, 9H), 0.19 (s, 6H), 0.163 (s, 3H), 0.159 (s, 3H). ¹³C {¹H} NMR (101 MHz, CDCl₃) δ 156.9, 153.4, 146.3, 140.5, 133.0, 117.8, 116.9, 116.8, 116.1, 102.7, 94.3, 84.0, 82.0, 81.3, 56.0, 35.0, 26.5, 26.0, 18.5, 18.4, -4.0, -4.07, -4.14. IR (KBr) $\nu_{\max}$ 3052, 2957, 2930, 2898, 2858, 1607, 1508, 1424, 1361, 1265, 1165, 839, 740 cm⁻¹; HRMS (ESI): calcd for C₃₁H₄₆NaO₅Si₂ [M + Na]⁺ 577.2776, found 577.2776.

(*S*)-2-(3-(4-(Methoxymethoxy)phenyl)prop-2-yn-1-yl)-2,3-dihydrofuro[2,3-*d*]oxepin-7(5H)-one ((*S*)-17a). To a solution of (*S*)-16a (1.2 g, 2.2 mmol) in THF (50 mL) was added tetrabutylammonium fluoride (2 M in THF, 1.1 mL), and the resultant mixture was stirred at 0 °C for 5 min. The reaction was quenched with saturated aqueous NH₄Cl (10 mL), and the resultant mixture was extracted with ethyl acetate (3 × 20 mL). The organic extracts were washed with saturated aqueous NaCl (2 × 20 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude was dissolved in MeCN (20 mL), and Ceric ammonium nitrate (1.0 M in H₂O, 4.8 mL) was added dropwise at 0 °C. Ethyl acetate (10 mL) was added to the reaction immediately, and the resultant mixture was extracted with ethyl acetate (3 × 20 mL). The organic extracts were washed with saturated aqueous NaCl (2 × 20 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give the crude product benzoquinone. The benzoquinone was dissolved in anhydrous CH₂Cl₂ at 0 °C, *m*-CPBA (75%) (504 mg, 2.2 mmol) was added to the solution. After the completion of the reaction, the solvent was removed under reduced pressure. the residue was quickly purified through thin pad of silica gel (hexanes/EtOAc, 2:1) to give crude product

anhydride as a yellow oil. The crude product is used directly for the next step. The crude product anhydride was added to a solution of NaBH₄ (29 mg, 0.77 mmol) in 5 mL of dry THF at 0 °C. After the completion of the reaction, the reaction was treated by slow addition of 1.0 M HCl until all the solid had dissolved. The resulting solution was extracted with ethyl acetate (3 × 10 mL). The combined organic solution was washed with saturated aqueous NaCl (2 × 10 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (hexanes/EtOAc, 8:1) to give (*S*)-**17a** (148 mg, 21% for 4 steps) as a colorless oil. $[\alpha]_D^{20} +26.0$ (c 1.00, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.29 (d, *J* = 8.7 Hz, 2H), 6.95 (d, *J* = 8.7 Hz, 2H), 6.43 – 6.37 (m, 1H), 5.72 (s, 1H), 5.16 (s, 2H), 4.80 – 4.72 (m, 1H), 4.54 (m, 2H), 3.46 (s, 3H), 3.08 (dd, *J* = 15.6, 7.3 Hz, 1H), 2.89 (dd, *J* = 15.6, 5.4 Hz, 1H), 2.79 (m, 2H). ¹³C {¹H}NMR (101 MHz, CDCl₃) δ 169.0, 166.2, 157.2, 140.2, 133.0, 127.5, 116.1, 95.9, 94.2, 83.2, 82.0, 80.5, 62.5, 56.1, 35.2, 25.9. IR (KBr) ν_{max} 3055, 2986, 2960, 2927, 2853, 1690, 1607, 1509, 1393, 1266, 1237, 1153, 838, 740cm⁻¹; HRMS (ESI): calcd for C₁₉H₁₉O₅ [M + H]⁺ 327.1227, found 327.1227.

(*R*)-2-(3-(4-(Methoxymethoxy)phenyl)prop-2-yn-1-yl)-2,3-dihydrofuro[2,3-*d*]oxepin-7(5H)-one ((*R*)-17b**).** Prepared according to the above steps. Colorless oil (162 mg, 23% for 4 steps). $[\alpha]_D^{20} -43.0$ (c 1.00, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.30 (d, *J* = 8.7 Hz, 2H), 6.95 (d, *J* = 8.7 Hz, 2H), 6.43 – 6.38 (m, 1H), 5.73 (s, 1H), 5.16 (s, 2H), 4.80 – 4.70 (m, 1H), 4.55 (m, 2H), 3.46 (s, 3H), 3.09 (dd, *J* = 15.7, 7.5 Hz, 1H), 2.90 (dd, *J* = 16.1, 5.6 Hz, 1H), 2.85 – 2.71 (m, 2H). ¹³C {¹H}NMR (101 MHz, CDCl₃) δ 169.0, 166.2, 157.2, 140.3, 133.0, 127.5, 116.2, 95.9, 94.3, 83.3, 82.0, 80.6, 62.6, 56.1, 35.2, 25.9. IR (KBr) ν_{max} 3055, 2986, 2958, 2926, 2853, 1690, 1608, 1509, 1393, 1265, 1237, 1153, 838, 739cm⁻¹; HRMS (ESI): calcd for C₁₉H₁₉O₅ [M + H]⁺

327.1227, found 327.1227.

(S)-2-(3-(4-Hydroxyphenyl)prop-2-yn-1-yl)-2,3-dihydrofuro[2,3-d]oxepin-7(5H)-one

((S)-18a). Compound (S)-17a (105 mg, 0.32 mmol) was dissolved in acetonitrile/H₂O = 5/0.1 (10 mL). BiCl₃ (31 mg, 0.10 mmol) was added to this solution. The mixture was stirred for 1 h at 50 °C. The reaction was treated by slow addition of 1.0 M HCl and extracted with ethyl acetate (3 × 10 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by a flash column chromatography (hexanes/EtOAc, 2:1) to give (S)-18a (82 mg, 90%) as a colorless oil. $[\alpha]_D^{20} +44.0$ (c 0.50, MeOH); ¹H NMR (400 MHz, DMSO) δ 9.78 (s, 1H), 7.18 (d, *J* = 8.6 Hz, 2H), 6.72 (d, *J* = 8.7 Hz, 2H), 6.61 – 6.54 (m, 1H), 5.54 (s, 1H), 4.81 (m, 1H), 4.51 (m, 2H), 3.12 (dd, *J* = 15.8, 7.5 Hz, 1H), 2.89 – 2.74 (m, 3H). ¹³C {¹H}NMR (101 MHz, DMSO) δ 168.1, 166.4, 157.6, 139.9, 132.8, 128.6, 115.5, 112.8, 94.5, 82.82, 82.76, 80.8, 62.3, 34.4, 25.1. IR (KBr) $\nu_{\max}$ 3361, 2974, 2893, 1668, 1611, 1513, 1453, 1328, 1272, 1187, 1049, 881, 837, 740 cm⁻¹; HRMS (ESI): calcd for C₁₇H₁₅O₄ [M + H]⁺ 283.0965, found 283.0966.

(R)-2-(3-(4-Hydroxyphenyl)prop-2-yn-1-yl)-2,3-dihydrofuro[2,3-d]oxepin-7(5H)-one

((R)-18b). Prepared according to the above step. Colorless oil (84 mg, 93%). $[\alpha]_D^{20} -46.0$ (c 1.00, MeOH); ¹H NMR (400 MHz, DMSO) δ 9.79 (s, 1H), 7.18 (d, *J* = 8.6 Hz, 2H), 6.72 (d, *J* = 8.7 Hz, 2H), 6.61 – 6.54 (m, 1H), 5.54 (s, 1H), 4.85 – 4.77 (m, 1H), 4.58 – 4.44 (m, 2H), 3.12 (dd, *J* = 15.8, 7.5 Hz, 1H), 2.88 – 2.75 (m, 3H). ¹³C {¹H}NMR (101 MHz, DMSO) δ 168.1, 166.4, 157.6, 140.0, 132.8, 128.6, 115.6, 112.8, 94.5, 82.83, 82.78, 80.8, 62.3, 34.4, 25.1. IR (KBr) $\nu_{\max}$ 3373, 3055, 2975, 2923, 2894, 1670, 1611, 1513, 1449, 1382, 1267, 1186, 1048, 880, 839, 741 cm⁻¹; HRMS (ESI): calcd for C₁₇H₁₅O₄ [M + H]⁺ 283.0965, found 283.0968.

(S, Z)-2-(3-(4-Hydroxyphenyl)allyl)-2,3-dihydrofuro[2,3-d]oxepin-7(5H)-one ((S)-1a). To a

solution of (*S*)-**18a** (50 mg, 0.18 mmol) in ethyl acetate (5 mL) was added quinoline (4.6 μ L, 10% in weight) followed by Lindlar's catalyst (10.0 mg, 20% in weight). This solution was stirred under a balloon of hydrogen for 1.5 h. The reaction mixture was filtered through a plug of silica and the solvent removed in vacuo; purification by Silver nitrate silica gel column chromatography yielded (*S*)-**1a** (45 mg, 89%) as a white powder. $[\alpha]_D^{20}$ -10.6 (c 0.23, MeOH); ^1H NMR (400 MHz, CDCl_3) δ 7.13 (d, J = 8.4 Hz, 2H), 6.82 (d, J = 8.6 Hz, 2H), 6.55 (d, J = 11.4 Hz, 1H), 6.34 (m, 1H), 5.69 (s, 1H), 5.53 (dt, J = 11.7, 7.2 Hz, 1H), 4.62 (m, 1H), 4.59 – 4.52 (m, 2H), 2.95 (dd, J = 15.4, 7.1 Hz, 1H), 2.75 (dd, J = 14.1, 7.3 Hz, 1H), 2.64 (dt, J = 16.1, 7.8 Hz, 2H). ^{13}C $\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 169.3, 166.4, 154.8, 140.6, 132.1, 130.0, 129.4, 127.4, 123.4, 115.3, 112.3, 95.6, 82.6, 62.6, 35.6, 33.8. IR (KBr) ν_{max} 2986, 2853, 1652, 1609, 1516, 1402, 1197, 1026, 841 cm^{-1} ; HRMS (ESI): calcd for $\text{C}_{17}\text{H}_{17}\text{O}_4$ $[\text{M} + \text{H}]^+$ 285.1121, found 285.1122.

(*R*, *Z*)-2-(3-(4-Hydroxyphenyl)allyl)-2,3-dihydrofuro[2,3-d]oxepin-7(5H)-one ((*R*)-1b**).**

Prepared according to the above step. White powder (43 mg, 86%). $[\alpha]_D^{20}$ +11.1 (c 0.29, MeOH); ^1H NMR (400 MHz, CDCl_3) δ 7.13 (d, J = 8.5 Hz, 2H), 6.82 (d, J = 8.6 Hz, 2H), 6.55 (d, J = 11.7 Hz, 1H), 6.34 (m, 1H), 5.69 (s, 1H), 5.54 (dt, J = 11.7, 7.2 Hz, 1H), 5.39 (br, 1H), 4.62 (m, 1H), 4.59 – 4.52 (m, 2H), 2.95 (dd, J = 15.5, 7.0 Hz, 1H), 2.80 – 2.71 (m, 1H), 2.70 – 2.56 (m, 2H). ^{13}C $\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 169.4, 166.4, 154.9, 140.6, 132.2, 130.0, 129.3, 127.4, 123.3, 115.3, 95.6, 82.7, 62.6, 35.6, 33.8. IR (KBr) ν_{max} 3015, 2867, 1649, 1612, 1513, 1396, 1183, 1020, 841 cm^{-1} ; HRMS (ESI): calcd for $\text{C}_{17}\text{H}_{17}\text{O}_4$ $[\text{M} + \text{H}]^+$ 285.1121, found 285.1123.

5-Ethynyl-2-methoxyphenol (20). To a solution of the aldehyde **19** (10 g, 0.066 mol) in dry CH_2Cl_2 (150 mL), triphenylphosphine (43.6 g, 0.13 mmol) was added under argon atmosphere. The resulting solution was cooled at 0 $^\circ\text{C}$ and a solution of carbon tetrabromide (69 g, 0.26 mmol)

in dry CH_2Cl_2 was added dropwise. The reaction mixture was stirred for 2 h and quenched adding water (100 mL). The organic layer was separated and washed with brine (2×50 mL), dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by a flash column chromatography (hexanes/EtOAc, 4:1) to give dibromoethene derivative as a white solid. *n*-BuLi (2.4 M, 47.3 mL) was added slowly to a solution containing the dibromoethene derivative (10.6 g, 0.034 mol) in dry THF cooled at -78 °C. The resulting solution was stirred at -78 °C for 1h then warmed slowly to room temperature, after the completion of the reaction, the mixture was quenched with water (50 mL) and extracted with ethyl acetate (3×50 mL). The combined organic solution was washed with saturated aqueous NH_4Cl (10 mL), dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by a flash column chromatography (hexanes/EtOAc, 4:1) to give **20** (11.9 g, 86%) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.05 (d, $J = 1.9$ Hz, 1H), 7.03 (dd, $J = 8.2, 2.0$ Hz, 1H), 6.78 (d, $J = 8.2$ Hz, 1H), 5.60 (s, 1H), 3.90 (s, 3H), 2.97 (s, 1H). ^{13}C $\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 147.3, 145.3, 124.8, 118.1, 114.9, 110.4, 83.6, 75.6, 55.9. Consistent with the literature report.¹

4-Ethynyl-1-methoxy-2-(methoxymethoxy)benzene (21). MOMCl (4.1 mL, 0.055 mmol) was added to a stirred solution of **20** (6.2 g, 0.042 mol) in CH_2Cl_2 (100 mL) at 0 °C. Diisopropylethyl amine (11.1 mL, 0.067 mmol) was slowly added to the reaction mixture. The ice bath was removed and the mixture was stirred at room temperature for 2 h. water (15 mL) was added in the reaction mixture, and the organic phase was separated and washed with 1 M of HCl, water, 1 M of NaOH, and brine. The organic phase was dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by a flash column chromatography (hexanes/EtOAc, 8:1) to give **21** (7.9 g, 98%) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ

7.28 (d, $J = 1.9$ Hz, 1H), 7.14 (dd, $J = 8.4, 1.9$ Hz, 1H), 6.81 (d, $J = 8.4$ Hz, 1H), 5.21 (s, 2H), 3.87 (s, 3H), 3.50 (s, 3H), 2.98 (s, 1H). ^{13}C $\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 150.5, 146.0, 126.9, 119.9, 114.3, 111.4, 95.4, 83.5, 75.7, 56.2, 55.8; IR (KBr) ν_{max} 3296, 3056, 2958, 2839, 2105, 1601, 1511, 1263, 1130, 925, 812, 738cm^{-1} ; HRMS (ESI): calcd for $\text{C}_{11}\text{H}_{13}\text{O}_3$ $[\text{M} + \text{H}]^+$ 193.0859, found 193.0859.

(*S*)-1-(2-Bromo-4,5-bis((*tert*-butyldimethylsilyl)oxy)phenyl)-5-(4-methoxy-3-(methoxymethoxy)phenyl)pent-4-yn-2-ol ((*S*)-22a). To a solution of **21** (4.6 g, 24.0 mmol) in dry THF (80 mL) Under argon atmosphere was added *n*-BuLi (2.4 M, 12.0 mL, 28.8 mmol) at -78°C . The mixture was stirred at -78°C for 1 h, (*R*)-**7a** (11.3 g, 24.0 mmol) in anhydrous THF and $\text{BF}_3\cdot\text{OEt}_2$ (3.0 mL, 24.0 mmol) was slowly added. After the completion of the reaction, the resulting solution was quenched with water (50 mL) and extracted with ethyl acetate (3×50 mL). The combined organic solution was washed with saturated aqueous NaCl (10 mL), dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by a flash column chromatography (hexanes/EtOAc, 8:1) to give (*S*)-**22a** (14.7 g, 92%) as a colorless oil. $[\alpha]_{\text{D}}^{20}$ -490 (c 1.00, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.24 (d, $J = 1.9$ Hz, 1H), 7.08 (dd, $J = 8.4, 1.9$ Hz, 1H), 7.00 (s, 1H), 6.82 (s, 1H), 6.80 (d, $J = 8.4$ Hz, 1H), 5.21 (s, 2H), 4.15 – 4.04 (m, 1H), 3.87 (s, 3H), 3.51 (s, 3H), 3.01 (dd, $J = 13.7, 5.7$ Hz, 1H), 2.86 (dd, $J = 13.7, 7.3$ Hz, 1H), 2.61 (ddd, $J = 22.9, 16.8, 5.6$ Hz, 2H), 2.01 (s, 1H), 0.98 (s, 9H), 0.97 (s, 9H), 0.21 – 0.18 (m, 12H). ^{13}C $\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 149.9, 146.4, 146.3, 146.1, 130.1, 126.3, 124.8, 123.7, 119.6, 115.7, 114.8, 111.4, 95.5, 84.2, 83.2, 69.7, 56.2, 55.9, 42.0, 27.4, 25.9, 25.8, 18.40, 18.36, -4.1, -4.15, -4.20, -4.24. IR (KBr) ν_{max} 3397, 3055, 2929, 2857, 1595, 1510, 1422, 1385, 1265, 846, 739cm^{-1} ; HRMS (ESI): calcd for $\text{C}_{32}\text{H}_{50}\text{BrO}_6\text{Si}_2$ $[\text{M} + \text{H}]^+$ 665.2324, found 665.2323.

(*R*)-1-(2-Bromo-4,5-bis((*tert*-butyldimethylsilyl)oxy)phenyl)-5-(4-methoxy-3-(methoxymethoxy)phenyl)pent-4-yn-2-ol ((*R*)-22b). Prepared according to the above step. Colorless oil (14.3 g, 90%). $[\alpha]_D^{20} +47.0$ (c 1.00, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.24 (d, *J* = 1.8 Hz, 1H), 7.09 (dd, *J* = 8.4, 1.8 Hz, 1H), 7.00 (s, 1H), 6.81 (d, 2H), 5.21 (s, 2H), 4.14 – 4.05 (m, 1H), 3.88 (s, 3H), 3.51 (s, 3H), 3.01 (dd, *J* = 13.7, 5.7 Hz, 1H), 2.86 (dd, *J* = 13.7, 7.4 Hz, 1H), 2.62 (qd, *J* = 16.7, 5.6 Hz, 2H), 1.79 (s, 1H), 0.98 (s, 9H), 0.97 (s, 9H), 0.20 (s, 6H), 0.19 (s, 6H). ¹³C {¹H}NMR (101 MHz, CDCl₃) δ 150.0, 146.4, 146.3, 146.2, 130.1, 126.4, 124.9, 123.7, 119.7, 115.8, 114.8, 111.5, 95.6, 84.3, 83.2, 69.8, 56.2, 55.9, 42.0, 27.5, 25.89, 25.86, 18.44, 18.41, -4.1, -4.17, -4.20. IR (KBr) $\nu_{\max}$ 3426, 3054, 2957, 2931, 2859, 1600, 1494, 1442, 1386, 1265, 842, 739 cm⁻¹; HRMS (ESI): calcd for C₃₂H₅₀BrO₆Si₂ [M + H]⁺ 665.2324, found 665.2325.

(*S*)-((2-(3-(4-Methoxy-3-(methoxymethoxy)phenyl)prop-2-yn-1-yl)-2,3-dihydrobenzofuran-5,6-diyl)bis(oxy))bis(*tert*-butyldimethylsilane) ((*S*)-23a). To a solution of (*S*)-22a (5.1 g, 7.66 mmol) in dry toluene (100 mL) under argon atmosphere, NaH (60%) (377 mg, 9.42 mmol) was added. The mixture was stirred at 40 °C for 15 min. Then, the mixture was cooled to rt and CuCl (30.3 mg, 0.31 mmol) was added to the solution. The suspension was stirred for at reflux and after this time, the mixture was filtered through Celite®. Then, the mixture was purified by flash column chromatography (hexanes/EtOAc, 16:1) to give (*S*)-23a (4.02 g, 90%) as a colorless oil. $[\alpha]_D^{20} +32.0$ (c 1.00, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.19 (d, *J* = 1.9 Hz, 1H), 7.02 (dd, *J* = 8.4, 1.9 Hz, 1H), 6.78 (d, *J* = 8.4 Hz, 1H), 6.65 (s, 1H), 6.34 (s, 1H), 5.21 (s, 2H), 4.92 (tt, *J* = 8.8, 7.1 Hz, 1H), 3.87 (s, 3H), 3.51 (s, 3H), 3.29 (dd, *J* = 15.5, 8.8 Hz, 1H), 3.04 (dd, *J* = 15.6, 6.6 Hz, 1H), 2.80 (ddd, *J* = 24.1, 16.6, 6.4 Hz, 2H), 0.98 (s, 9H), 0.97 (s, 9H), 0.20 – 0.15 (m, 12H). ¹³C {¹H}NMR (101 MHz, CDCl₃) δ 153.4, 149.9, 146.2, 146.1, 140.5, 126.4, 119.6, 117.8, 117.0,

115.8, 111.4, 102.7, 95.5, 83.8, 82.0, 81.3, 56.2, 55.9, 35.0, 26.5, 25.99, 25.96, 18.5, 18.4, -4.06, -4.08, -4.15, -4.2. IR (KBr) $\nu_{\max}$ 3053, 2956, 2930, 2898, 2858, 1603, 1509, 1424, 1361, 1259, 1165, 839, 782, 739 cm^{-1} ; HRMS (ESI): calcd for $\text{C}_{32}\text{H}_{48}\text{NaO}_6\text{Si}_2$ $[\text{M} + \text{Na}]^+$ 607.2882, found 607.2881.

(*R*)-((2-(3-(4-Methoxy-3-(methoxymethoxy)phenyl)prop-2-yn-1-yl)-2,3-dihydrobenzofuran-5,6-diyl)bis(oxy))bis(tert-butyldimethylsilane) ((*R*)-23b). Prepared according to the above step. Colorless oil (3.9 g, 87%). $[\alpha]_{\text{D}}^{20}$ -22.0 (c 1.00, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 7.19 (d, J = 1.8 Hz, 1H), 7.02 (dd, J = 8.4, 1.8 Hz, 1H), 6.78 (d, J = 8.4 Hz, 1H), 6.65 (s, 1H), 6.34 (s, 1H), 5.21 (s, 2H), 4.93 (dt, J = 14.1, 7.0 Hz, 1H), 3.86 (s, 3H), 3.51 (s, 3H), 3.29 (dd, J = 15.3, 8.9 Hz, 1H), 3.04 (dd, J = 15.3, 6.6 Hz, 1H), 2.80 (ddd, J = 24.0, 16.6, 6.4 Hz, 2H), 0.98 (s, 9H), 0.97 (s, 9H), 0.21 – 0.14 (m, 12H). ^{13}C $\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 153.4, 149.9, 146.2, 146.0, 140.5, 126.4, 119.5, 117.7, 116.9, 115.8, 111.4, 102.7, 95.5, 83.8, 82.0, 81.3, 56.2, 55.8, 35.0, 26.5, 26.0, 25.9, 18.44, 18.36, -4.07, -4.10, -4.16, -4.18. IR (KBr) $\nu_{\max}$ 3054, 2956, 2930, 2899, 2858, 1603, 1511, 1424, 1361, 1262, 1165, 840, 783, 739 cm^{-1} ; HRMS (ESI): calcd for $\text{C}_{32}\text{H}_{48}\text{NaO}_6\text{Si}_2$ $[\text{M} + \text{Na}]^+$ 607.2882, found 607.2881.

(*S*)-2-(3-(4-Methoxy-3-(methoxymethoxy)phenyl)prop-2-yn-1-yl)-2,3-dihydrofuro[2,3-d]oxepin-7(5H)-one ((*S*)-24a). To a solution of (*S*)-23a (1.2 g, 2.1 mmol) in THF (50 mL) was added tetrabutylammonium fluoride (2 M in THF, 2.1 mL), and the resultant mixture was stirred at 0 °C for 5 min. The reaction was quenched with saturated aqueous NH_4Cl (10 mL), and the resultant mixture was extracted with ethyl acetate (3 $\times$ 20 mL). The organic extract was washed with saturated aqueous NaCl (2 $\times$ 20 mL), dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The crude was dissolved in MeCN (20 mL), and Ceric ammonium nitrate (1.0 M in H_2O ,

4.6 mL) was added dropwise at 0 °C. Ethyl acetate (10 mL) was added to the reaction immediately, and the resultant mixture was extracted with ethyl acetate (3 × 20 mL). The organic extract was washed with saturated aqueous NaCl (2 × 20 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give the crude product benzoquinone. The benzoquinone was dissolved in anhydrous CH₂Cl₂ at 0 °C, *m*-CPBA (75%) (482 mg, 2.1 mmol) was added to the solution. After the completion of the reaction, the solvent was removed under reduced pressure. the residue was quickly purified through thin pad of silica gel (hexanes/EtOAc, 2:1) to give crude product anhydride as a yellow oil. The crude product is used directly for the next step. The crude product anhydride was added to a solution of NaBH₄ (25 mg, 0.66 mmol) in 5 mL of dry THF at 0 °C. After the completion of the reaction, the reaction was treated by slow addition of 1.0 M HCl until all the solid had dissolved. The resulting solution was extracted with ethyl acetate (3 × 10 mL). The combined organic solution was washed with saturated aqueous NaCl (2 × 10 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography (hexanes/EtOAc, 8:1) to give (*S*)-**24a** (132 mg, 18% for 4 steps) as a colorless oil. $[\alpha]_D^{20} +18.0$ (c 1.00, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.16 (d, *J* = 1.9 Hz, 1H), 7.03 (dd, *J* = 8.4, 1.9 Hz, 1H), 6.80 (d, *J* = 8.4 Hz, 1H), 6.45 – 6.38 (m, 1H), 5.73 (s, 1H), 5.21 (s, 2H), 4.81 – 4.71 (m, 1H), 4.55 (d, *J* = 5.8 Hz, 2H), 3.87 (s, 3H), 3.51 (s, 3H), 3.10 (dd, *J* = 16.3, 7.2 Hz, 1H), 2.90 (dd, *J* = 15.7, 4.6 Hz, 1H), 2.79 (qd, *J* = 16.9, 5.7 Hz, 2H). ¹³C {¹H}NMR (101 MHz, CDCl₃) δ 169.0, 166.2, 150.1, 146.1, 140.2, 127.5, 126.3, 119.3, 115.1, 111.5, 95.9, 95.5, 83.2, 81.8, 80.5, 62.6, 56.3, 55.9, 35.2, 25.9. IR (KBr) ν_{max} 3055, 2987, 2928, 2854, 1691, 1603, 1512, 1422, 1394, 1265, 1183, 896, 740cm⁻¹; HRMS (ESI): calcd for C₂₀H₂₁O₆ [M + H]⁺ 357.1333, found 357.1332.

(*R*)-2-(3-(4-Methoxy-3-(methoxymethoxy)phenyl)prop-2-yn-1-yl)-2,3-dihydrofuro[2,3-*d*]oxepin-7(5*H*)-one ((*R*)-24*b*). Prepared according to the above steps. Colorless oil (139 mg, 19% for 4 steps). $[\alpha]_D^{20}$ -17.0 (c 1.00, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 7.15 (d, *J* = 1.9 Hz, 1H), 7.01 (dd, *J* = 8.4, 1.9 Hz, 1H), 6.79 (d, *J* = 8.4 Hz, 1H), 6.42 – 6.35 (m, 1H), 5.71 (s, 1H), 5.19 (s, 2H), 4.77 – 4.69 (m, 1H), 4.53 (d, *J* = 5.8 Hz, 2H), 3.86 (s, 3H), 3.49 (s, 3H), 3.13 – 3.02 (m, 1H), 2.92 – 2.84 (m, 1H), 2.83 – 2.69 (m, 2H). ¹³C {¹H}NMR (101 MHz, CDCl₃) δ 168.9, 166.2, 150.1, 146.1, 140.2, 127.5, 126.3, 119.3, 115.1, 111.5, 95.8, 95.4, 83.2, 81.7, 80.4, 62.5, 56.2, 55.9, 35.2, 25.9. IR (KBr) $\nu_{\max}$ 3055, 2978, 2927, 2848, 1689, 1618, 1512, 1442, 1394, 1265, 1183, 896, 739cm⁻¹; HRMS (ESI): calcd for C₂₀H₂₁O₆ [M + H]⁺ 357.1333, found 357.1334.

(*S*)-2-(3-(3-Hydroxy-4-methoxyphenyl)prop-2-yn-1-yl)-2,3-dihydrofuro[2,3-*d*]oxepin-7(5*H*)-one ((*S*)-25*a*). Compound (*S*)-24*a* (66 mg, 0.19 mmol) was dissolved in acetonitrile/H₂O = 5/0.1 (10 mL). BiCl₃ (17.5 mg, 0.057 mmol) was added to this solution. The mixture was stirred for 1 h at 50 °C. The reaction was treated by slow addition of 1.0 M HCl and extracted with ethyl acetate (3 × 10 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by a flash column chromatography (hexanes/EtOAc, 2:1) to give (*S*)-25*a* (53 mg, 91%) in yield as a colorless oil. $[\alpha]_D^{20}$ +29.0 (c 1.00, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 6.92 (d, *J* = 1.7 Hz, 1H), 6.92 – 6.88 (m, 1H), 6.76 (d, *J* = 8.3 Hz, 1H), 6.41 (m, 1H), 5.73 (s, 1H), 5.62 (s, 1H), 4.80 – 4.72 (m, 1H), 4.55 (m, 2H), 3.89 (s, 3H), 3.09 (dd, *J* = 15.8, 7.5 Hz, 1H), 2.90 (dd, *J* = 15.4, 6.1 Hz, 1H), 2.79 (qd, *J* = 16.9, 5.7 Hz, 2H). ¹³C {¹H}NMR (101 MHz, CDCl₃) δ 169.0, 166.2, 147.0, 145.3, 140.3, 127.5, 124.2, 117.6, 115.6, 110.4, 95.9, 83.3, 81.6, 80.5, 62.6, 55.9, 35.2, 25.9. IR (KBr) $\nu_{\max}$ 3404, 3055, 2918, 2849, 1688, 1618, 1511, 1442, 1394, 1266, 1183, 895, 845, 738cm⁻¹; HRMS (ESI): calcd for C₁₈H₁₇O₅ [M + H]⁺ 313.1071, found 313.1071.

(*R*)-2-(3-(3-Hydroxy-4-methoxyphenyl)prop-2-yn-1-yl)-2,3-dihydrofuro[2,3-*d*]oxepin-7(5H)-one ((*R*)-25b). Prepared according to the above step. Colorless oil (51 mg, 89%). $[\alpha]_D^{20}$ -26.0 (c 1.00, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 6.92 (d, *J* = 1.9 Hz, 1H), 6.90 (dd, *J* = 8.2, 1.9 Hz, 1H), 6.76 (d, *J* = 8.3 Hz, 1H), 6.43 – 6.38 (m, 1H), 5.73 (s, 1H), 5.62 (s, 1H), 4.83 – 4.72 (m, 1H), 4.61 – 4.51 (m, 2H), 3.89 (s, 3H), 3.09 (dd, *J* = 15.4, 7.5 Hz, 1H), 2.90 (dd, *J* = 15.8, 5.6 Hz, 1H), 2.78 (qd, *J* = 16.9, 5.7 Hz, 2H). ¹³C {¹H}NMR (101 MHz, CDCl₃) δ 169.0, 166.2, 147.0, 145.3, 140.3, 127.5, 124.2, 117.6, 115.6, 110.5, 96.0, 83.3, 81.6, 80.5, 62.6, 55.9, 35.2, 25.9. IR (KBr) $\nu_{\max}$ 3375, 3055, 2926, 2849, 1689, 1618, 1512, 1442, 1394, 1266, 1183, 896, 845, 739 cm⁻¹; HRMS (ESI): calcd for C₁₈H₁₇O₅ [M + H]⁺ 313.1071, found 313.1072.

(*S*, *Z*)-2-(3-(3-Hydroxy-4-methoxyphenyl)allyl)-2,3-dihydrofuro[2,3-*d*]oxepin-7(5H)-one ((*S*)-3a). To a solution of (*S*)-25a (43 mg, 0.14 mmol) in ethyl acetate (2 mL) was added quinoline (3.9 μ L, 10% in weight) followed by Lindlar's catalyst (8.6 mg, 20% in weight). This solution was stirred under a balloon of hydrogen for 1.5 h. The reaction mixture was filtered through a plug of silica and the solvent removed in vacuo; purification by Silver nitrate silica gel column chromatography yielded (*S*)-3a (38 mg, 88%) as a white solid. $[\alpha]_D^{20}$ -13.0 (c 0.45, MeOH); ¹H NMR (400 MHz, CDCl₃) δ 6.85 – 6.0 (m, 2H), 6.73 (dd, *J* = 8.3, 1.9 Hz, 1H), 6.51 (d, *J* = 11.6 Hz, 1H), 6.34 (ddd, *J* = 7.8, 5.7, 2.0 Hz, 1H), 5.68 (s, 1H), 5.54 (dt, *J* = 11.6, 7.2 Hz, 1H), 4.63 (m, 1H), 4.61 – 4.52 (m, 2H), 3.89 (s, 3H), 2.94 (dd, *J* = 15.5, 7.1 Hz, 1H), 2.80 – 2.71 (m, 1H), 2.70 – 2.56 (m, 2H). ¹³C {¹H}NMR (101 MHz, CDCl₃) δ 169.1, 166.2, 145.7, 145.3, 140.5, 132.2, 130.3, 127.4, 123.8, 120.8, 114.7, 110.5, 95.7, 82.6, 62.5, 56.0, 35.6, 33.8. IR (KBr) $\nu_{\max}$ 3386, 3054, 2912, 1689, 1615, 1510, 1396, 1274, 1185, 1129, 1026 cm⁻¹; HRMS (ESI): calcd for C₁₈H₁₈NaO₅ [M + H]⁺ 337.1046, found 337.1050.



(*R*, *Z*)-2-(3-(3-Hydroxy-4-methoxyphenyl)allyl)-2,3-dihydrofuro[2,3-*d*]oxepin-7(5H)-one ((*R*)-3b). Prepared according to the above step. White solid (39 mg, 90%). $[\alpha]_{\text{D}}^{20} +13.8$ (c 0.25, MeOH); ^1H NMR (400 MHz, CDCl_3) δ 6.85 – 6.81 (m, 2H), 6.74 (dd, $J = 8.3, 1.9$ Hz, 1H), 6.52 (d, $J = 11.6$ Hz, 1H), 6.37 – 6.32 (m, 1H), 5.69 (s, 1H), 5.55 (dt, $J = 11.6, 7.2$ Hz, 1H), 4.62 (t, $J = 6.5$ Hz, 1H), 4.59 – 4.52 (m, 2H), 3.90 (s, 3H), 2.95 (dd, $J = 15.4, 7.1$ Hz, 1H), 2.80 – 2.71 (m, 1H), 2.71 – 2.57 (m, 2H). ^{13}C $\{^1\text{H}\}$ NMR (101 MHz, CDCl_3) δ 169.1, 166.2, 145.7, 145.3, 140.5, 132.2, 130.3, 127.4, 123.8, 120.8, 114.7, 110.5, 95.7, 82.6, 62.5, 56.0, 35.6, 33.8. IR (KBr) ν_{max} 3392, 2993, 2915, 1683, 1609, 1516, 1396, 1271, 1185, 1026 cm^{-1} ; HRMS (ESI): calcd for $\text{C}_{18}\text{H}_{18}\text{NaO}_5$ $[\text{M} + \text{H}]^+$ 337.1046, found 337.1042.

REFERENCES



- (1) Pagliai, F.; Pirali, T.; Grosso, E. D.; Brisco, R. D.; Tron, G. C.; Sorba, G.; Genazzani, A. A. Rapid Synthesis of Triazole-Modified Resveratrol Analogues via Click Chemistry. *J. Med. Chem.* **2006**, *49*, 467-470.

¹H and ¹³C NMR spectra of synthetic compounds

LS-20MeBr-I



LS-20MeBr-I





LS-2TBSBR1

— 7.26
— 7.07

— 0.97

— 0.20
— 0.19



LS-2TBSBR1-C

— 148.08
— 147.03

— 131.63

— 124.65

— 120.21



— 89.41



— 77.32
— 77.00
— 76.68



— 25.89
— 25.82



— 18.43



— 4.20
— 4.22





















































































































LS-3RTMOM703



icon_5_1ZU_LS_20180705_3RTMOM703



LS-3S0H3j609



LS-3S0H3j609

